Romanian drug company expands US exports after FDA green light

29 January 2013

Pharmaceutical company Antibiotice Iasi is expanding exports to the USA following a regular control and the approval by the US Food and Drug Administration (FDA). The US agency checked Antibiotice Iasi between January 14 and 22 this year, as all pharmaceutical producers wishing to sell medicines in the US must pass an FDA inspection;.

Antibiotice Iasi already sells  the amino-penicillin antibiotic ampicillin as a solution for injection in four different concentration to the US market. The pharmaceutical firm will also starts exports of anti-fungal drug nyastin and another antibiotic nafcillin to the US in 2013.

New exports are expected to start in the first quarter of 2013 and the company hopes the FDA approval will help expansion to other markets, such as Australia, South America, Canada and South Africa. The vote of confidence from the US agency will also be a useful tool when promoting the company in emerging markets in Asia and the Middle East.

In 2012,  Antibiotice Iasi's exports valued around USD 20 million – a big increase from the USD 5 million in exports registered in 2007. The company estimates that sales will increase by 17 percent on last year in 2013. Antibiotice  Iasi, majority owned by the Romanian state via the Health Ministry, exports pharmaceutical products to 60 countries worldwide through more than 100 business partners.

editor@romania-insider.com

(photo source: The company)

Normal

Romanian drug company expands US exports after FDA green light

29 January 2013

Pharmaceutical company Antibiotice Iasi is expanding exports to the USA following a regular control and the approval by the US Food and Drug Administration (FDA). The US agency checked Antibiotice Iasi between January 14 and 22 this year, as all pharmaceutical producers wishing to sell medicines in the US must pass an FDA inspection;.

Antibiotice Iasi already sells  the amino-penicillin antibiotic ampicillin as a solution for injection in four different concentration to the US market. The pharmaceutical firm will also starts exports of anti-fungal drug nyastin and another antibiotic nafcillin to the US in 2013.

New exports are expected to start in the first quarter of 2013 and the company hopes the FDA approval will help expansion to other markets, such as Australia, South America, Canada and South Africa. The vote of confidence from the US agency will also be a useful tool when promoting the company in emerging markets in Asia and the Middle East.

In 2012,  Antibiotice Iasi's exports valued around USD 20 million – a big increase from the USD 5 million in exports registered in 2007. The company estimates that sales will increase by 17 percent on last year in 2013. Antibiotice  Iasi, majority owned by the Romanian state via the Health Ministry, exports pharmaceutical products to 60 countries worldwide through more than 100 business partners.

editor@romania-insider.com

(photo source: The company)

Normal
 

facebooktwitterlinkedin

1

Romania Insider Free Newsletters